Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4269902 | 1.00 | TDP1 (0.46) | TDP1SERPINE1MEN1GAAKMT2A | |
| SCHEMBL6131611 | 0.91 | MEN1 (0.47) | TDP1SERPINE1MEN1GAAKMT2A | |
| SCHEMBL3165185 | 0.88 | SERPINE1 (0.46) | TDP1SERPINE1MEN1GAAKMT2A | |
| SCHEMBL3156606 | 0.88 | SERPINE1 (0.46) | TDP1SERPINE1MEN1GAAKMT2A | |
| SCHEMBL8741650 | 0.84 | SERPINE1 (0.43) | TDP1SERPINE1MEN1GAAKMT2A | |
| SCHEMBL23990995 | 0.80 | SERPINE1 (0.43) | TDP1SERPINE1MEN1GAAKMT2A | |
| SCHEMBL12143608 | 0.79 | MEN1 (0.47) | TDP1SERPINE1MEN1GAAKMT2A | |
| SCHEMBL17860156 | 0.79 | TDP1 (0.50) | TDP1SERPINE1MEN1GAAKMT2A | |
| SCHEMBL7518298 | 0.79 | TDP1 (0.50) | TDP1SERPINE1MEN1GAAKMT2A | |
| SCHEMBL18991085 | 0.79 | SERPINE1 (0.42) | TDP1SERPINE1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022136641-A1 | IONIZABLE LIPIDS | ETHERNA IMMUNOTHERAPIES NV (BE) | 2022-06-30 | — | — | WO | disclosed |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| CN-110891954-A | Inhibitors of leucine-rich repeat kinase 2 | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-03-17 | — | — | CN | disclosed |
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1644334-B1 | ANTITHROMBOTIC ETHERS | LILLY CO ELI (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1644334-A1 | ANTITHROMBOTIC ETHERS | Eli Lilly and Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004108677-A1 | ANTITHROMBOTIC ETHERS | ELI LILLY AND COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108594-A1 | Antithrombotic Ethers | F11, SERPINC1, F2 | TDP1 1110/4885SERPINE1 28/4885MEN1 441/4885 |
| US-20200392158-A1 | INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | LRRK2, PARK7, PINK1 | TDP1 450/4885SERPINE1 2032/4885MEN1 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.